• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Neovascular Glaucoma.新生血管性青光眼
Dev Ophthalmol. 2016;55:196-204. doi: 10.1159/000431196. Epub 2015 Oct 26.
2
A review of neovascular glaucoma. Etiopathogenesis and treatment.新生血管性青光眼的综述。病因发病机制与治疗。
Rom J Ophthalmol. 2021 Oct-Dec;65(4):315-329. doi: 10.22336/rjo.2021.66.
3
Neovascular Glaucoma: An Update.新生血管性青光眼:最新进展
Klin Monbl Augenheilkd. 2023 Mar;240(3):305-315. doi: 10.1055/a-1956-9348. Epub 2022 Nov 27.
4
Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases.玻璃体内注射贝伐单抗治疗41例连续性缺血性视网膜疾病继发的虹膜新生血管和新生血管性青光眼。
Ophthalmology. 2008 Sep;115(9):1571-80, 1580.e1-3. doi: 10.1016/j.ophtha.2008.02.026. Epub 2008 Apr 28.
5
Intravitreal bevacizumab combined with panretinal photocoagulation in the treatment of open angle neovascular glaucoma.玻璃体内注射贝伐单抗联合全视网膜光凝治疗开角型新生血管性青光眼。
Eur J Ophthalmol. 2009 Nov-Dec;19(6):1028-33. doi: 10.1177/112067210901900620.
6
Panretinal photocoagulation with simultaneous cryoretinopexy or intravitreal bevacizumab for neovascular glaucoma.全视网膜光凝联合冷冻视网膜固定术或玻璃体腔内贝伐单抗治疗新生血管性青光眼。
Graefes Arch Clin Exp Ophthalmol. 2013 May;251(5):1355-60. doi: 10.1007/s00417-012-2236-9. Epub 2012 Dec 19.
7
Bevacizumab as adjuvant for neovascular glaucoma.贝伐单抗作为新生血管性青光眼的辅助治疗。
Acta Ophthalmol. 2010 Feb;88(1):103-9. doi: 10.1111/j.1755-3768.2008.01355.x. Epub 2009 Sep 20.
8
[Neovascular glaucoma--etipathogeny and diagnosis].[新生血管性青光眼——病因及诊断]
Oftalmologia. 2012;56(2):3-14.
9
Neovascular glaucoma: etiology, diagnosis and prognosis.新生血管性青光眼:病因、诊断与预后
Semin Ophthalmol. 2009 Mar-Apr;24(2):113-21. doi: 10.1080/08820530902800801.
10
A Review of Neovascular Glaucoma: Etiology, Pathogenesis, Diagnosis, and Treatment.新生血管性青光眼:病因、发病机制、诊断与治疗的综述。
Medicina (Kaunas). 2022 Dec 18;58(12):1870. doi: 10.3390/medicina58121870.

引用本文的文献

1
Intraocular pressure variation (ocular hypertension) in diabetes mellitus.糖尿病中的眼压变化(高眼压症)
World J Clin Cases. 2025 Oct 6;13(28):107263. doi: 10.12998/wjcc.v13.i28.107263.
2
Effect of combined therapy based on transscleral peripheral retinal cryotherapy in the treatment of open-angle neovascular glaucoma: a retrospective study.经巩膜周边视网膜冷冻术联合治疗开角型新生血管性青光眼的疗效:一项回顾性研究
BMC Ophthalmol. 2025 Jul 1;25(1):375. doi: 10.1186/s12886-025-04185-7.
3
A Comparison of All-Cause Mortality in Patients Who Required Glaucoma Surgery for Neovascular Glaucoma or Primary Open-Angle Glaucoma: A Retrospective Cohort Study.因新生血管性青光眼或原发性开角型青光眼而需要进行青光眼手术的患者全因死亡率比较:一项回顾性队列研究
Vision (Basel). 2025 Jun 13;9(2):49. doi: 10.3390/vision9020049.
4
The pivotal role of inflammatory factors in glaucoma: a systematic review.炎症因子在青光眼发病机制中的关键作用:一项系统综述
Front Immunol. 2025 May 23;16:1577200. doi: 10.3389/fimmu.2025.1577200. eCollection 2025.
5
Combined Posterior Vitrectomy and Ahmed Valve Implantation with Prior Antiangiogenic Application for the Management of Neovascular Glaucoma: A Case Series Study.联合后段玻璃体切除术及艾哈迈德引流阀植入术并预先应用抗血管生成药物治疗新生血管性青光眼:一项病例系列研究
J Curr Glaucoma Pract. 2025 Jan-Mar;19(1):3-7. doi: 10.5005/jp-journals-10078-1462. Epub 2025 Mar 24.
6
Causes and prognosis of neovascular glaucoma after pars plana vitrectomy in patients with diabetic retinopathy.糖尿病性视网膜病变患者行玻璃体切除术后新生血管性青光眼的病因及预后
BMC Ophthalmol. 2025 Mar 28;25(1):159. doi: 10.1186/s12886-025-03984-2.
7
The causal effect of glaucoma and diabetic retinopathy: a Mendelian randomization study.青光眼与糖尿病视网膜病变的因果效应:一项孟德尔随机化研究。
Diabetol Metab Syndr. 2025 Mar 5;17(1):80. doi: 10.1186/s13098-025-01652-5.
8
Effectiveness and safety of intravitreal aflibercept injection for neovascular glaucoma: A single-center, retrospective, observational study in China.玻璃体内注射阿柏西普治疗新生血管性青光眼的有效性和安全性:中国一项单中心、回顾性、观察性研究
Medicine (Baltimore). 2025 Feb 28;104(9):e41538. doi: 10.1097/MD.0000000000041538.
9
Interplay Between Ocular Ischemia and Glaucoma: An Update.眼缺血与青光眼的相互作用:最新研究进展。
Int J Mol Sci. 2024 Nov 19;25(22):12400. doi: 10.3390/ijms252212400.
10
Utilizing retinal arteriole/venule ratio to estimate intracranial pressure.利用视网膜小动脉/小静脉比值估计颅内压。
Acta Neurochir (Wien). 2024 Nov 8;166(1):445. doi: 10.1007/s00701-024-06343-0.

本文引用的文献

1
Recent advances in the management of neovascular glaucoma.新生血管性青光眼治疗的最新进展
Semin Ophthalmol. 2013 May;28(3):165-72. doi: 10.3109/08820538.2012.730103.
2
Ocular neovascularization following central retinal artery occlusion: prevalence and timing of onset.视网膜中央动脉阻塞后的眼部新生血管形成:发生率及发病时间
Eur J Ophthalmol. 2010 Nov-Dec;20(6):1042-6. doi: 10.1177/112067211002000603.
3
Subconjunctival bevacizumab as an adjunct to trabeculectomy in eyes with refractory glaucoma: a case series.结膜下注射贝伐单抗辅助难治性青光眼小梁切除术:病例系列
Korean J Ophthalmol. 2010 Feb;24(1):47-52. doi: 10.3341/kjo.2010.24.1.47. Epub 2010 Feb 5.
4
The Ahmed glaucoma valve in neovascular glaucoma (An AOS Thesis).阿赫迈德青光眼引流阀在新生血管性青光眼中的应用(一篇美国眼科学会论文)
Trans Am Ophthalmol Soc. 2009 Dec;107:325-42.
5
Anti-VEGF therapy for glaucoma.抗血管内皮生长因子治疗青光眼。
Curr Opin Ophthalmol. 2010 Mar;21(2):112-7. doi: 10.1097/ICU.0b013e3283360aad.
6
Evaluation of subconjunctival bevacizumab as an adjunct to trabeculectomy a pilot study.小梁切除术辅助结膜下注射贝伐单抗的评估:一项初步研究
Ophthalmology. 2008 Dec;115(12):2141-2145.e2. doi: 10.1016/j.ophtha.2008.06.009. Epub 2008 Aug 9.
7
Intravitreal bevacizumab and augmented trabeculectomy for neovascular glaucoma in young diabetic patients.玻璃体内注射贝伐单抗联合增强型小梁切除术治疗年轻糖尿病患者新生血管性青光眼。
Eye (Lond). 2009 Apr;23(4):979-81. doi: 10.1038/eye.2008.113. Epub 2008 May 2.
8
Intracameral bevacizumab for iris rubeosis.前房内注射贝伐单抗治疗虹膜新生血管。
Am J Ophthalmol. 2006 Jul;142(1):158-60. doi: 10.1016/j.ajo.2006.02.045.
9
Needle bleb revision of encapsulated filtering bleb with bevacizumab.使用贝伐单抗对包裹性滤过泡进行针刺性水泡修复术。
Ophthalmic Surg Lasers Imaging. 2006 Mar-Apr;37(2):148-50.
10
Intravitreal bevacizumab in a patient with neovascular glaucoma.玻璃体内注射贝伐单抗治疗新生血管性青光眼患者。
Ophthalmic Surg Lasers Imaging. 2006 Mar-Apr;37(2):144-6.

新生血管性青光眼

Neovascular Glaucoma.

作者信息

Havens Shane J, Gulati Vikas

出版信息

Dev Ophthalmol. 2016;55:196-204. doi: 10.1159/000431196. Epub 2015 Oct 26.

DOI:10.1159/000431196
PMID:26501989
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5664957/
Abstract

Neovascular glaucoma (NVG) is a secondary ocular pathological condition resulting from a myriad of ocular and systemic conditions with retinal ischemia as a mediator in over 95% of cases. NVG is caused by the growth of a fibrovascular membrane secondary to a local angiogenic stimulus over the trabecular meshwork obstructing aqueous outflow. This results in an initial secondary open-angle glaucoma stage that may be amenable to intraocular pressure (IOP)-lowering medications and modulation of the underlying ischemic process, often in combination with panretinal photocoagulation and adjunctive use of vascular endothelial growth factor inhibitors. In the more advanced stages of neovascularization, connective tissue myofibroblasts associated with new vessel growth contract causing progressive synechial closure of the anterior-chamber angle. Elevation of IOP, once significant secondary angle closure is established, tends to be refractory to topical and oral IOP-lowering medications and often requires glaucoma surgical interventions.

摘要

新生血管性青光眼(NVG)是一种继发性眼部病理状况,由多种眼部和全身疾病引起,在超过95%的病例中以视网膜缺血为介导因素。NVG是由小梁网局部血管生成刺激继发的纤维血管膜生长所致,该纤维血管膜阻碍房水流出。这会导致最初的继发性开角型青光眼阶段,此时可能适合使用降低眼压(IOP)的药物并调节潜在的缺血过程,通常联合全视网膜光凝和血管内皮生长因子抑制剂的辅助使用。在新生血管形成的更晚期阶段,与新血管生长相关的结缔组织肌成纤维细胞收缩,导致前房角逐渐发生粘连性关闭。一旦形成明显的继发性房角关闭,眼压升高往往对局部和口服降眼压药物难治,通常需要进行青光眼手术干预。